Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three phase III trials.

ABSTRACT: BACKGROUND:Cough and sputum are troublesome symptoms in chronic obstructive pulmonary disease (COPD) and are associated with adverse outcomes. The efficacy of aclidinium bromide 400?µg twice daily in patients with stable COPD has been established in two phase III studies (ACCORD COPD I and ATTAIN) and a phase IIIb active-comparator study. This analysis evaluated cough-related symptoms across these studies. METHOD:Patients were randomised to placebo, aclidinium 200?µg or 400?µg twice daily in ACCORD (12?weeks) and ATTAIN (24?weeks), or to placebo, aclidinium 400?µg twice daily or tiotropium 18?µg once daily (6-week active-comparator study). Analysed end points included changes from baseline in Evaluating Respiratory Symptoms (E-RS; formerly known as EXAcerbations of Chronic pulmonary disease Tool), total and cough/sputum scores and frequency/severity of morning and night-time cough and sputum symptoms. RESULTS:Data for 1792 patients were evaluated. E-RS cough/sputum domain scores were significantly reduced with aclidinium 400?µg versus placebo in ATTAIN (-0.7 vs -0.3, respectively; p<0.01) and the active-comparator study (-0.6 vs -0.2, respectively; p<0.01). In the active-comparator study, significantly greater improvements were observed with aclidinium versus placebo for severity of morning cough (-0.19 vs -0.02; p<0.01) and phlegm (-0.19 vs -0.02; p<0.05). In ACCORD, aclidinium reduced night-time cough frequency (-0.36 vs 0.1 for placebo; p<0.001) and severity (-0.24 vs -0.1 for placebo; p<0.05), and frequency of night-time sputum production (-0.37 vs 0.05 for placebo; p<0.001). CONCLUSIONS:Aclidinium 400?µg twice daily improves cough and sputum expectoration versus placebo in stable COPD. TRIAL REGISTRATION NUMBERS:NCT00891462; NCT01001494; NCT01462929.

SUBMITTER: McGarvey L 

PROVIDER: S-EPMC5174811 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature